새로운 항생제의 개발

키워드

참고문헌 (65)

1. Rice LB, "Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE", J Infect Dis, 197, pp.1079~1081 (2008)
2. "Infectious Diseases Society of America. The epidemic of antibiotic resistant infections: a call to action for the medical community from the Infectious Diseases Society of America", Clin Infect Dis, 46, pp.155~164 (2008)
3. Sakoulas G, "Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy", Clin Infect Dis, 42, pp.S40~S50 (2006)
4. Robert J, "Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: a 20 year study in a large French teaching hospital, 1983-2002", J Antimicrob Chemother, 57, pp.506~510 (2006)
5. Bradley JS, "Anti-infective research and development-problems, challenges, and solutions", Lancet Infect Dis, 7, pp.68~78 (2007)
6. 이경원, "High Prevalence of Ceftazidime-Resistant Klebsiella pneumoniae and Increase of Imipenem-Resistant", Yonsei Medical Journal, 47(5), pp.634~645 (2006), 연세대학교의과대학
7. Micek ST, "Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections", Clin Infect Dis, 15, pp.S184~S190 (2007)
8. Boucher HW, "Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America", Clin Infect Dis, 48, pp.1~12 (2009)
9. Enoch DA, "Daptomycin", J Infection, 55, pp.205~213 (2007)
10. Arbeit RD, "The safety and efficacy of daptomycin for the treatment of complicated kin and skin-structure infections", Clin Infect Dis, 38, pp.1673~1681 (2004)
11. Fowler Jr VG, "Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus", N Engl J Med, 344, pp.653~665 (2006)
12. Rybak MJ, "The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria", Clin Microbiol Infect, 12, pp.24~32 (2006)
13. Sakoulas G, "Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin", Antimicrob Agents Chemother, 50, pp.1581~1585 (2006)
14. Arias CA, "Failure of daptomycin monotherapy for endocarditis caused by an Enterococcus faecium strain with vancomycin-resistant and vancomycin-susceptible subpopulations and evidence of in vivo loss of the vanA gene cluster", Clin Infect Dis, 45, pp.1343~1346 (2007)
15. Sakoulas G, "Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus", Clin Infect Dis, 45, pp.601~608 (2007)
16. Pankey GA, "Tigecycline", J Antimicrob Chemother, 56, pp.470~480 (2005)
17. Stein GE, "Tigecycline : A Critical Analysis", Clin Infect Dis, 43, pp.518~524 (2006)
18. No authors listed, "Ceftobiprole Medocaril: BAL5788, JNJ 30982081, JNJ30982081, RO 65-5788, RO 655788", Drugs R D, 7, pp.305~311 (2006)
19. Noel GJ, "A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections", Clin Infect Dis, 46, pp.647~655 (2008)
20. Denis O, "In vitro activities of ceftobiprole, Tigecycline, Daptomycin and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitals", Antimicrob Agents Chemother, 50, pp.2680~2685 (2006)
21. Chambers HF, "Ceftobiprole: in vivo profile of a bactericidal cephalosporin", Clin Microbiol Infect, 12, pp.17~22 (2006)
22. Murthy B, "Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity", Clin Pharmacokinet, 47, pp.21~33 (2008)
23. Zhanel GG, "Ceftaroline: A Novel Broad-Spectrum Cephalosporin with Activity against Meticillin-Resistant Staphylococcus aureus", Drugs, 69, pp.809~831 (2009)
24. Sader HS, "Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains", Antimicrob Agents Chemother, 49, pp.3501~3512 (2005)
25. Jacqueline C, "In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model", Antimicrob Agents Chemother, 51, pp.3397~3400 (2007)
26. Talbot GH, "Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections", Antimicrob Agents Chemother, 51, pp.3612~3616 (2007)
27. Chen AY, "Dalbavancin: a novel antimicrobial", Int J Clin Pract, 61, pp.853~863 (2007)
28. Decousser JW, "Dalbavancin, a long-acting lipoglycopeptide for the treatment of multidrug-resistant Gram-positive bacteria", Expert Rev Anti Infect Ther, 5, pp.557~571 (2007)
29. Kim A, "Review of dalbavancin, a novel semisynthetic lipoglycopeptide", Expert Opin Investig Drugs, 16, pp.717~733 (2007)
30. Scheinfeld N, "Dalbavancin: a review", Drugs Today, 43, pp.305~316 (2007)
31. Cavaleri M, "Pharmacokinetics and excretion of dalbavancin in the rat", J Antimicrob Chemother, 55, pp.ii31~ii35 (2005)
32. Leighton A, "Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers", Antimicrob Agents Chemother, 48, pp.940~945 (2004)
33. Jauregui LE, "Randomized, double-blind comparison of onceweekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections", Clin Infect Dis, 41, pp.1407~1415 (2005)
34. Seltzer E, "l. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections", Clin Infect Dis, 37, pp.1298~1303 (2003)
35. Goldstein BP, "Microbiologic characterization of isolates from a dalbavancin clinical trial for catheter-related bloodstream infections", Diagn Microbiol Infect Dis, 54, pp.83~87 (2006)
36. Ward KE, "Oritavancin - an investigational glycopeptide antibiotic", Expert Opin Investig Drugs, 15, pp.417~429 (2006)
37. Mercier RC, "Oritavancin: a new avenue for resistant Gram-positive bacteria", Expert Rev Anti Infect Ther, 3, pp.325~332 (2005)
38. Biavasco F, "In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide", Antimicrob Agents Chemother, 41, pp.2165~2172 (1997)
39. Van Bambeke F, "Cellular pharmacokinetics and pharmacodynamics of the glycopeptide antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages", Antimicrob Agents Chemother, 48, pp.2853~2860 (2004)
40. Fetterly GJ, "Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose", Antimicrob Agents Chemother, 49, pp.148~152 (2005)
41. Anderson DL, "Oritavancin for skin infections", Drugs Today, 44, pp.563~575 (2008)
42. Kanafani ZA, "Telavancin: a new lipoglycopeptide with multiple mechanisms of action", Expert Rev Anti Infect Ther, 4, pp.743~749 (2006)
43. Laohavaleeson S, "Telavancin: a novel lipoglycopeptide for serious gram-positive infections", Expert Opin Investig Drugs, 16, pp.347~357 (2007)
44. Stucki A, "Efficacy of telavancin against penicillin-resistant pneumococci and Staphylococcus aureus in a rabbit meningitis model and determination of kinetic parameters", Antimicrob Agents Chemother, 50, pp.770~773 (2006)
45. Shaw JP, "Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects", Antimicrob Agents Chemother, 49, pp.195~201 (2005)
46. Sun HK, "Tissue penetration of telavancin after intravenous administration in healthy subjects", Antimicrob Agents Chemother, 50, pp.788~790 (2006)
47. Pace JL, "In vitro activity of TD-6424 against Staphylococcus aureus", Antimicrob Agents Chemother, 47, pp.3602~3604 (2003)
48. Stryjewski ME, "Assessment of Telavancin in Complicated Skin and Skin-Structure Infections Study. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms", Clin Infect Dis, 46, pp.1683~1693 (2008)
49. Fung-Tomc JC, "Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756", Antimicrob Agents Chemother, 44, pp.3351~3356 (2000)
50. Jones RN, "Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values", Diagn Microbiol Infect Dis, 58, pp.9~17 (2007)
51. Gajjar DA, "Multiple-dose safety and pharmacokinetics of oral garenoxacin in healthy subjects", Antimicrob Agents Chemother, 47, pp.2256~2263 (2003)
52. Van Wart S, "Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections", Antimicrob Agents Chemother, 48, pp.4766~4777 (2004)
53. Krishna G, "Effect of an aluminum- and magnesium-containing antacid on the bioavailability of garenoxacin in healthy volunteers", Pharmacotherapy, 27, pp.963~969 (2007)
54. Krishna G, "The effect of omeprazole on the bioavailability and safety of garenoxacin in healthy volunteers", J Clin Pharmacol, 47, pp.628~632 (2007)
55. Takagi H, "Clinical studies of garenoxacin", Int J Antimicrob Agents, 32, pp.468~474 (2008)
56. Hawser S, "Dihydrofolate reductase inhibitors as antibacterial agents", Biochem Pharmacol, 71, pp.941~948 (2006)
57. Schneider P, "Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria", Bioorg Med Chem Lett, 13, pp.4217~4221 (2003)
58. Andrews J, "Concentrations in plasma, epithelial lining fluid, alveolar macrophages and bronchial mucosa after a single intravenous dose of 1.6 mg", kg of iclaprim (AR-100) in healthy men, 2007, pp.60, 677~680
59. Laue H, "In vitro activity of the novel diaminopyrimidine, iclaprim, in combination with folate inhibitors and other antimicrobials with different mechanisms of action", J Antimicrob Chemother, 60, pp.1391~1394 (2007)
60. French GL, "What’s new and not so new on the antimicrobial horizon?", Clin Microbiol Infect, 14, pp.S19~S29 (2008)
61. "Doripenem: S 4661", Drugs R D, 4, pp.363~365 (2003)
62. Lister PD, "Carbapenems in the USA: focus on doripenem", Expert Rev Anti Infect Ther, 5, pp.793~809 (2007)
63. Jones RN, "Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms", Diagn Microbiol Infect Dis, 52, pp.71~74 (2005)
64. Fritsche TR, "Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003)", Clin Microbiol Infect, 11, pp.974~984 (2005)
65. Zhanel GG, "Comparative review of the carbapenems", Drugs, 67, pp.1027~1052 (2007)

관련 논문AI추천